

RESPONSE


Claims 1-92 are pending in the subject application. The election, described below, identifies claims 10-47 and 82-92 for further prosecution.

In response to the restriction requirement among Groups 1-46, Applicant elects Group 21 (SEQ ID NO: 4) as the invention peptide for further prosecution. Applicant further elects a formulation comprising beta-interferon (β -interferon). Accordingly, Applicant elects linking claims 1-47 and 82-92 insofar as these claims recite the invention to be examined.

Applicant makes these elections with traverse and without waiver as to right to rejoinder or under 103(b).


Examination of the elected claims and subject matter is respectfully requested.

Respectfully Submitted,



Peter J. Knudsen, Esq.
Attorney/Agent for Applicants
Reg. No. 40,682
January 30, 2006 Date

Peter J. Knudsen
3450 Monte Villa Parkway
Bothell, Washington 98021-8909
Tel. 425-908-3643
Facsimile: 425-908-3653
pknudsen@nastech.com

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence of <u>22</u> pages is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.			
Signature			
Typed or printed name	Patricia J. Utter	Date	January 30, 2006